Dataset
Dataset: covid-19_results_mar_dec_2020.zip, 1.22 GB
Access Condition: Open access

Documentation: efficacy_of_fda_approved_hiv_drugs_on_sars-cov-2.txt, 720 bytes
Access Condition: Open access
Description:
Methodology description (English)

Please login to the repository to save this object to your list.
Cite this document

Tomić, D. (2021). Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein [Data set]. https://urn.nsk.hr/urn:nbn:hr:241:733364.

Tomić, Draško. Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein. Institut Ruđer Bošković, 2021. 21 May 2022. https://urn.nsk.hr/urn:nbn:hr:241:733364.

Tomić, Draško. 2021. Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein. Institut Ruđer Bošković. https://urn.nsk.hr/urn:nbn:hr:241:733364.

Tomić, D. 2021. Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein. Institut Ruđer Bošković. [Online]. [Accessed 21 May 2022]. Available from: https://urn.nsk.hr/urn:nbn:hr:241:733364.

Tomić D. Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein. [Internet]. Institut Ruđer Bošković: , HR; 2021, [cited 2022 May 21] Available from: https://urn.nsk.hr/urn:nbn:hr:241:733364.

D. Tomić, Results of the efficacy of FDA approved antiviral drugs on SARS-CoV-2 spike glycoprotein, Institut Ruđer Bošković, 2021. Accessed on: May 21, 2022. Available: https://urn.nsk.hr/urn:nbn:hr:241:733364.